Anticoagulation on haemodyalisis: perspectives of low molecular weight heparins in dyalisis optimization


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Role of low molecular weight heparins in anticoagulation in patients on chronic hemodyalisis is discussed. Results of clinical trials, demonstrating their advantages beyond unfractioned heparin, are reviewed.

Full Text

Restricted Access

References

  1. European Best Practice Guidelines. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002; 17(Suppl. 7): 63-71.
  2. Европейские рекомендации по оптимальной практике гемодиализа (часть 1). Нефрология и диализ. 2005; (Прил.): 65—74.
  3. Martinez-Gonzalez J., Rodriguez C. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin. Expert Rev Cardiovasc Ther. 2010; 8(5): 625-634.
  4. Greaves M. Control of anticoagulation subcommittee of the scientific and standardization committee of the International Society of Thrombosis and Haemostasis. Limitations of the laboratory monitoring of heparin therapy. Scientific and standardization committee communications on behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemostst. 2002; 87: 163—164.
  5. Kirwan C.J., Baig Z.F., Platton S. et al. Anti-Xa Activity Supports Using a Simple Dosing Algorithm for Tinzaparin for Anticoagulation in Hemodialysis. Nephron. Clin. Pract. 2013; 123(1-2): 7-12.
  6. Davenport A., Lai K.N., Hertel J. et al. Anticoagulation. In: Daugirdas J.T., Blake P.G., Ing T.S. (eds). Handbook of Dialysis, 4th edn. Amsterdam: Wolters Kluwer Health. 2007; 204—218.
  7. Herrero-Calvo J.A., González-Parra E., Pérez-Garcia R. et al. Spanish study of anticoagulation in haemodialysis. Nefrologia. 2012; 32(2): 143—152.
  8. Lim W., Cook D.J., Crowther M.A. Safety and efficacy of low molecular weight heparins for haemodialysis patients with end stage renal failure: A meta-analysis of randomised controlled trials. J. Am. Soc. Nephrol. 2004; 15: 192-206.
  9. Козловская Н.Л., Котлярова Г.В., Сафонов В.В. и соавт. Влияние нефракционированного и низкомолекулярного гепаринов на параметры внутрисосудистого свертывания крови у больных, получающих лечение программным гемодиализом. Нефрология и диализ. 2007; Т. 9. № 1.
  10. Naumnik B., Borawski J., Mysliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. Nephrol Dial Transplant 2003; 18(7): 1376-1382.
  11. Naumnik B., Pawlak K., Mysliwiec M. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study. Clin. Appl. Thromb. Hemost. 2009; 15(1): 84-91.
  12. Deuber H.J., Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int. 1991; 40: 496-500.
  13. Lai K.N., Ho K., Cheung R.C. et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidaemia in patients on maintenance haemodialysis. Int. J. Artif. Organs. 2001; 24: 447-455.
  14. Oster J.R., Singer I., Fishman L.M. Heparin induced aldosterone suppression and hyperkalemia. Am. J. Med. 1995; 98: 575-86.
  15. Charif R., Davenport A. Heparin-induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy. Hemodial. Int. 2006; 10: 235-240.
  16. Шило В. Ю., Хасабов Н. Н., Денисов А. Ю. Низкомолекулярные гепарины у больных на программном гемодиализе: опыт применения фраксипарина. Нефрология и диализ. 2006. 8(2): 184-188.
  17. Stefansson B.V., Abramson M., Nilsson U. et al. Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration. Nephron Extra. 2012; 2: 55-65.
  18. Sombolos K.I., Fragia T.K., Gionanlis L.C. et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther. 2008; 46(4): 198-203.
  19. Dager W.E., Andersen J., Nutescu E. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 2004; 24(7pt 2): 88-94S.
  20. Kessler M., Gangemi C., Gutierrez Martones A. et al. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: a prospective proof-of-concept study. Hemodial Int. 2013; 17(2): 282-293.
  21. Шило В.Ю. Низкомолекулярные гепарины в гемодиализе: многолетний опыт применения далтепарина. Клиницист. 2008; 2: 55-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies